Find News

Filter articles

Applied Filters

Showing 101 to 110 of 127 results

AIDS group warns of TPP’s impact on access to generic medicine


The Foundation for AIDS Research has warned that the Trans-Pacific Partnership’s changes to IP policy could restrict access to affordable generic medicines in low and middle income countries.

Otsuka acquires Avanir in $3.5 billion deal

Japan02-12-2014Mergers & acquisitions

Japanese drug maker Otsuka Holdings has agreed to buy Avanir Pharmaceuticals as part of a multi-billion dollar deal that could ease its potential patent woes.

‘Worrying trend’ of Aussie counterfeit pharmaceuticals


Criminal gangs in Australia are branching away from traditional forms of counterfeiting and are targeting pharmaceuticals, an Australian customs official has revealed.

Cipla agrees Rifaximin licensing deal


Indian drug maker Cipla has signed a deal with Salix Pharmaceuticals allowing the US-based company exclusive rights relating to the Rifaximin Complexes patent family.

Australia suggests uprooting plant rights committee


The Australian government department responsible for IP has suggested abolishing a committee that looks after plant breeders’ rights as it looks at alternative means for giving advice to breeders.

Myriad cancer patent upheld in Australia


Companies in Australia will be able to continue to patent human genes after a court rejected an appeal by a breast cancer survivor.

Biotech industry reacts to USPTO’s Myriad/Mayo guidelines

Australia, EU, Japan, UK, US13-08-2014

A group of 12 international biotechnology associations has written to the US Patent and Trademark Office (USPTO), raising concerns about the office’s guidelines on determining the patent eligibility of natural products in the aftermath of the Myriad and Mayo cases.

NeuClone and Serum Institute collaborate on biosimilars

Australia, India08-07-2014

Australian biotechnology company NeuClone has signed an agreement with vaccine maker the Serum Institute of India to manufacture and supply ten biosimilar monoclonal antibody drugs around the world.

MMR Global and Claydata enter into licensing agreement


Personal health records company MMR Global has entered into a licensing agreement with Australian medical database company Claydata.

Canada and Australia in new stem cell partnership

Australia, Canada16-06-2014

Stem cell research companies in Canada and Australia have teamed up to support increased research and development in both countries.

Showing 101 to 110 of 127 results